Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis

Xu Li; Yuan Jiao; Yunlong Xing; Pujun Gao

doi:10.1155/2019/5308308

Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis

Biomed Res Int. 2019 Apr 4:2019:5308308. doi: 10.1155/2019/5308308. eCollection 2019.

Authors

Xu Li¹, Yuan Jiao², Yunlong Xing³, Pujun Gao¹

Affiliations

¹ Department of Hepatology, The First Hospital of Jilin University, Jilin University, No. 71 Xinmin Street, Changchun 130021, China.
² Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Jilin University, No. 126 Xiantai Street, Changchun 130033, China.
³ Department of Plastic Surgery, China-Japan Union Hospital of Jilin University, Jilin University, No. 126 Xiantai Street, Changchun 130033, China.

Abstract

Development of cirrhosis is two- to threefold greater in patients with diabetes mellitus (DM), and in this setting, the prevalence of cirrhosis is surging worldwide. The present review served to examine clinical ties between DM and liver fibrosis and hepatic cirrhosis and explore related biologic mechanisms. Pathways contributing to various etiologies of cirrhosis in conjunction with DM were key investigative targets.

Publication types

Review

MeSH terms

Alcoholism / epidemiology
Alcoholism / etiology
Diabetes Complications* / epidemiology
Diabetes Mellitus*
Glucose / metabolism
Hepacivirus
Hepatitis B / epidemiology
Hepatitis B / etiology
Hepatitis B virus / pathogenicity
Hepatitis C / epidemiology
Hepatitis C / etiology
Humans
Hypoglycemic Agents / adverse effects
Liver Cirrhosis / epidemiology*
Liver Cirrhosis / etiology*
Metformin / adverse effects
Non-alcoholic Fatty Liver Disease / epidemiology
Non-alcoholic Fatty Liver Disease / etiology
Prevalence
Prognosis
Risk Factors
Thiazolidinediones / adverse effects

Substances

Hypoglycemic Agents
Thiazolidinediones
Metformin
Glucose